Ryan Deschner
Stock Analyst at Raymond James
(2.74)
# 507
Out of 5,329 analysts
10
Total ratings
75.00%
Success rate
39.00%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
INZY Inozyme Pharma | Maintains: Outperform | 24 12 | 1.2 | 900% | 1 | Mar 12, 2025 | |
TRVI Trevi Therapeutics | Upgrades: Strong Buy | 9 29 | 6.92 | 319.08% | 2 | Mar 10, 2025 | |
ARDX Ardelyx | Reiterates: Strong Buy | 15 13 | 5.48 | 137.23% | 1 | Feb 21, 2025 | |
SPRY ARS Pharmaceuticals | Maintains: Strong Buy | 26 28 | 14.2 | 97.18% | 3 | Jan 14, 2025 | |
LQDA Liquidia | Upgrades: Strong Buy | 27 27 | 14.01 | 92.72% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 12 | n/a | n/a | 1 | Jun 18, 2024 |